<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="UTF-8">
<meta name="viewport" content="width=device-width, initial-scale=1, maximum-scale=2">
<meta name="theme-color" content="#222">
<meta name="generator" content="Hexo 3.9.0">
  <link rel="apple-touch-icon" sizes="180x180" href="/images/apple-touch-icon-next.png">
  <link rel="icon" type="image/png" sizes="32x32" href="/images/favicon-32x32-next.png">
  <link rel="icon" type="image/png" sizes="16x16" href="/images/favicon-16x16-next.png">
  <link rel="mask-icon" href="/images/logo.svg" color="#222">

<link rel="stylesheet" href="/css/main.css">


<link rel="stylesheet" href="/lib/font-awesome/css/font-awesome.min.css">


<script id="hexo-configurations">
  var NexT = window.NexT || {};
  var CONFIG = {
    hostname: new URL('http://hujiandong.com').hostname,
    root: '/',
    scheme: 'Muse',
    version: '7.7.0',
    exturl: false,
    sidebar: {"position":"left","display":"post","padding":18,"offset":12,"onmobile":false},
    copycode: {"enable":false,"show_result":false,"style":null},
    back2top: {"enable":true,"sidebar":false,"scrollpercent":false},
    bookmark: {"enable":false,"color":"#222","save":"auto"},
    fancybox: false,
    mediumzoom: false,
    lazyload: false,
    pangu: false,
    comments: {"style":"tabs","active":null,"storage":true,"lazyload":false,"nav":null},
    algolia: {
      appID: '',
      apiKey: '',
      indexName: '',
      hits: {"per_page":10},
      labels: {"input_placeholder":"Search for Posts","hits_empty":"We didn't find any results for the search: ${query}","hits_stats":"${hits} results found in ${time} ms"}
    },
    localsearch: {"enable":false,"trigger":"auto","top_n_per_article":1,"unescape":false,"preload":false},
    path: 'search.xml',
    motion: {"enable":true,"async":false,"transition":{"post_block":"fadeIn","post_header":"slideDownIn","post_body":"slideDownIn","coll_header":"slideLeftIn","sidebar":"slideUpIn"}}
  };
</script>

  <meta name="description" content="ELCC2019size: 202.59 MB |- Where nursing fits.pdf - 848.00 kB|- What is the role of surgery for stage III patients in the I-O era.pdf - 1.40 MB|- What is the biological rationale for combining chemoth">
<meta property="og:type" content="article">
<meta property="og:title" content="ELCC2019">
<meta property="og:url" content="http://hujiandong.com/2020/ELCC2019_790/index.html">
<meta property="og:site_name" content="Baidu Wang Pan">
<meta property="og:description" content="ELCC2019size: 202.59 MB |- Where nursing fits.pdf - 848.00 kB|- What is the role of surgery for stage III patients in the I-O era.pdf - 1.40 MB|- What is the biological rationale for combining chemoth">
<meta property="og:locale" content="en">
<meta property="og:updated_time" content="2020-01-19T05:10:54.409Z">
<meta name="twitter:card" content="summary">
<meta name="twitter:title" content="ELCC2019">
<meta name="twitter:description" content="ELCC2019size: 202.59 MB |- Where nursing fits.pdf - 848.00 kB|- What is the role of surgery for stage III patients in the I-O era.pdf - 1.40 MB|- What is the biological rationale for combining chemoth">

<link rel="canonical" href="http://hujiandong.com/2020/ELCC2019_790/">


<script id="page-configurations">
  // https://hexo.io/docs/variables.html
  CONFIG.page = {
    sidebar: "",
    isHome: false,
    isPost: true
  };
</script>

  <title>ELCC2019 | Baidu Wang Pan</title>
  
    <script async src="https://www.googletagmanager.com/gtag/js?id=UA-66670171-7"></script>
    <script>
      if (CONFIG.hostname === location.hostname) {
        window.dataLayer = window.dataLayer || [];
        function gtag(){dataLayer.push(arguments);}
        gtag('js', new Date());
        gtag('config', 'UA-66670171-7');
      }
    </script>






  <noscript>
  <style>
  .use-motion .brand,
  .use-motion .menu-item,
  .sidebar-inner,
  .use-motion .post-block,
  .use-motion .pagination,
  .use-motion .comments,
  .use-motion .post-header,
  .use-motion .post-body,
  .use-motion .collection-header { opacity: initial; }

  .use-motion .site-title,
  .use-motion .site-subtitle {
    opacity: initial;
    top: initial;
  }

  .use-motion .logo-line-before i { left: initial; }
  .use-motion .logo-line-after i { right: initial; }
  </style>
</noscript>

</head>

<body itemscope itemtype="http://schema.org/WebPage">
  <div class="container use-motion">
    <div class="headband"></div>

    <header class="header" itemscope itemtype="http://schema.org/WPHeader">
      <div class="header-inner"><div class="site-brand-container">
  <div class="site-meta">

    <div>
      <a href="/" class="brand" rel="start">
        <span class="logo-line-before"><i></i></span>
        <span class="site-title">Baidu Wang Pan</span>
        <span class="logo-line-after"><i></i></span>
      </a>
    </div>
  </div>

  <div class="site-nav-toggle">
    <div class="toggle" aria-label="Toggle navigation bar">
      <span class="toggle-line toggle-line-first"></span>
      <span class="toggle-line toggle-line-middle"></span>
      <span class="toggle-line toggle-line-last"></span>
    </div>
  </div>
</div>


<nav class="site-nav">
  
  <ul id="menu" class="menu">
        <li class="menu-item menu-item-home">

    <a href="/home" rel="section"><i class="fa fa-fw fa-home"></i>Home</a>

  </li>
        <li class="menu-item menu-item-archives">

    <a href="/archives/" rel="section"><i class="fa fa-fw fa-archive"></i>Archives</a>

  </li>
  </ul>

</nav>
</div>
    </header>

    
  <div class="back-to-top">
    <i class="fa fa-arrow-up"></i>
    <span>0%</span>
  </div>


    <main class="main">
      <div class="main-inner">
        <div class="content-wrap">
          

          <div class="content">
            

  <div class="posts-expand">
      
  
  
  <article itemscope itemtype="http://schema.org/Article" class="post-block " lang="en">
    <link itemprop="mainEntityOfPage" href="http://hujiandong.com/2020/ELCC2019_790/">

    <span hidden itemprop="author" itemscope itemtype="http://schema.org/Person">
      <meta itemprop="image" content="/images/avatar.gif">
      <meta itemprop="name" content="baidupan">
      <meta itemprop="description" content="baidupan">
    </span>

    <span hidden itemprop="publisher" itemscope itemtype="http://schema.org/Organization">
      <meta itemprop="name" content="Baidu Wang Pan">
    </span>
      <header class="post-header">
        <h1 class="post-title" itemprop="name headline">
          ELCC2019
        </h1>

        <div class="post-meta">
            <span class="post-meta-item">
              <span class="post-meta-item-icon">
                <i class="fa fa-calendar-o"></i>
              </span>
              <span class="post-meta-item-text">Posted on</span>
              

              <time title="Created: 2020-01-19 13:09:48 / Modified: 13:10:54" itemprop="dateCreated datePublished" datetime="2020-01-19T13:09:48+08:00">2020-01-19</time>
            </span>
            <span class="post-meta-item">
              <span class="post-meta-item-icon">
                <i class="fa fa-folder-o"></i>
              </span>
              <span class="post-meta-item-text">In</span>
                <span itemprop="about" itemscope itemtype="http://schema.org/Thing">
                  <a href="/categories/baidu/" itemprop="url" rel="index">
                    <span itemprop="name">baidu</span>
                  </a>
                </span>
            </span>

          

        </div>
      </header>

    
    
    
    <div class="post-body" itemprop="articleBody">

      
        <h1 id="ELCC2019"><a href="#ELCC2019" class="headerlink" title="ELCC2019"></a>ELCC2019</h1><p>size: 202.59 MB</p>
<p>|- Where nursing fits.pdf - 848.00 kB<br>|- What is the role of surgery for stage III patients in the I-O era.pdf - 1.40 MB<br>|- What is the biological rationale for combining chemotherapy with immune checkpoint inhibitors.pdf - 4.80 MB<br>|- What caregivers do for patients affected by cancer.pdf - 383.00 kB<br>|- What can LuCE achieve in terms of lobbying.pdf - 1.30 MB<br>|- Treatment options from the medical oncologist’s perspective.pdf - 1.50 MB<br>|- Treatment of localised disease.pdf - 3.00 MB<br>|- Treatment Duration of Brigatinib in Patients Enrolled in the International Expanded Access Program (EAP).pdf - 494.00 kB<br>|- Treatment algorithms for oligoprogressive and oligometastatic disease.pdf - 2.10 MB<br>|- TMB trumps PD-L1 as predictive biomarker for immuno-oncology therapy.pdf - 3.20 MB<br>|- TMB as predictor of immuno-oncology therapy.pdf - 2.40 MB<br>|- The role of the pathologist  Multiple primaries vs metastatic disease.pdf - 4.40 MB<br>|- The role of IASLC in helping to implement personalised medicine.pdf - 3.00 MB<br>|- The role of brain irradiation.pdf - 1.30 MB<br>|- The respiratory and medical oncology perspective.pdf - 1.20 MB<br>|- The radiation oncology perspective.pdf - 2.30 MB<br>|- The pathologist’s point of view.pdf - 3.20 MB<br>|- The experience and impact of cancer caregiving through the cancer continuum.pdf - 476.00 kB<br>|- The effect of prophylactic cranial irradiation (PCI) for young stage III NSCLC patients.pdf - 419.00 kB<br>|- Targeted therapy beyond EGFR, ALK and ROS1.pdf - 7.30 MB<br>|- Synchronous and metachronous primary tumours.pdf - 1.20 MB<br>|- Surgical decision  To operate or not to operate.pdf - 3.50 MB<br>|- Supporting lung cancer survivors  Living with and beyond lung cancer.pdf - 1.10 MB<br>|- Supporting lung cancer patients through virtual environments.pdf - 1.50 MB<br>|- STELLAR – Final updated results of a phase 2 trial of TTFields with chemotherapy for unresectable malignant pleural mesothelioma.pdf - 402.00 kB<br>|- should upfront ngs be our new standard of.pdf - 2.50 MB<br>|- Sequencing systemic therapy with driver mutations.pdf - 2.00 MB<br>|- Sequencing of I-O therapies.pdf - 1.60 MB<br>|- SCLC The surgeon´s point of view.pdf - 2.50 MB<br>|- SCLC The radiation oncologist’s point of view.pdf - 1.90 MB<br>|- SCLC The medical oncologist’s point of view.pdf - 4.50 MB<br>|- Safety and Efficacy of Pembrolizumab (Pembro) Monotherapy in Elderly Patients (Pts) With PD-L1–positive Advanced NSCLC.pdf - 1.50 MB<br>|- Role of radiotherapy in oligometastatic I-O progression.pdf - 446.00 kB<br>|- Robotic assisted lung resection for locally advanced lung cancer.pdf - 2.30 MB<br>|- Reflections from the French experience.pdf - 3.00 MB<br>|- Recommendation on second-line treatment according to first-line choice.pdf - 4.20 MB<br>|- RECaN  What this project has taught us about advanced roles.pdf - 1.70 MB<br>|- Radiogenomic signatures of NSCLC brain metastases.pdf - 1.10 MB<br>|- Quality of life after radical treatment for lung cancer.pdf - 4.00 MB<br>|- Progression on PD1 PD-L1 inhibitors  What is in the pipeline.pdf - 3.40 MB<br>|- Prevalence of programmed death ligand-1 (PD-L1) by demographic, disease and sample characteristics in unresectable, stage III NSCLC (PACIFIC).pdf - 327.00 kB<br>|- Predictive diagnostics and treatment algorithms.pdf - 4.50 MB<br>|- Potential resistance mechanisms using next generation sequencing from Chinese EGFR T790M+ non-small-cell lung cancer patients with primary resistan.pdf - 683.00 kB<br>|- Potential biomarkers for MPM in asbestos-exposed subjects.pdf - 4.10 MB<br>|- Phase 1 study of gefitinib (G) + durvalumab (D) .pdf - 634.00 kB<br>|- PD-L1 is superior to TMB as predictive biomarker for immuno-oncology therapy.pdf - 3.60 MB<br>|- Patient’s experience of the integrated model of care.pdf - 956.00 kB<br>|- Patient-reported outcomes (PROs) with durvalumab by PD-L1 expression in unresectable, Stage III NSCLC (PACIFIC).pdf - 555.00 kB<br>|- Overcoming resistance to immune checkpoint inhibitors.pdf - 7.50 MB<br>|- Oligometastatic NSCLC.pdf - 3.00 MB<br>|- Novel targets, new therapeutic strategies and future perspectives.pdf - 1.60 MB<br>|- Nivolumab (nivo) plus ipilimumab (ipi), nivo, or placebo (pbo) as maintenance therapy in patients (pts) with extensive disease small cell lung can.pdf - 472.00 kB<br>|- My patient needs surgery upfront followed by adjuvant treatment.pdf - 2.70 MB<br>|- My patient needs neoadjuivant treatment followed by surgery.pdf - 1.20 MB<br>|- Molecular targets and therapies for SCLC.pdf - 2.90 MB<br>|- Mentor guided discussion Role of radiotherapy in oligometastatic I-O progression.pdf - 714.00 kB<br>|- Mentor guided discussion ALK inhibitors best sequence.pdf - 1.90 MB<br>|- Management of pulmonary toxicities  Clinical case.pdf - 4.00 MB<br>|- Management of I-O toxicities  An introduction.pdf - 1.40 MB<br>|- Management of GI toxicities  Clinical case.pdf - 597.00 kB<br>|- Management of endocrine toxicities  Clinical case.pdf - 1.20 MB<br>|- Management of cough in patients with LC.pdf - 1.40 MB<br>|- Local treatment in oligoprogressive disease.pdf - 1.60 MB<br>|- Lobar vs. sublobar resections for stage I NSCLC.pdf - 1.60 MB<br>|- Is palliative care under threat for stigma.pdf - 168.00 kB<br>|- Invited Discussant 84O, 104O and 105O.pdf - 1.70 MB<br>|- Invited Discussant 83O, LBA2 and LBA4.pdf - 2.20 MB<br>|- Invited Discussant 68O and 69O.pdf - 1.80 MB<br>|- Invited Discussant 21O and 108O.pdf - 1.80 MB<br>|- Invited Discussant 109O, 55O and 110O.pdf - 4.00 MB<br>|- Intratumoural I-O A niche therapy.pdf - 3.30 MB<br>|- Integrating early palliative care to oncology care.pdf - 742.00 kB<br>|- IMpower150  an exploratory analysis of efficacy outcomes in patients with EGFR mutations.pdf - 1.00 MB<br>|- Importance of access to innovative treatments and their impact on patient reported outcomes.pdf - 1.00 MB<br>|- Impact of subsequent post-discontinuation immunotherapy on overall survival in patients with unresectable, Stage III NSCLC from PACIFIC.pdf - 389.00 kB<br>|- Impact of MET variants on PD-L1 expression in Pleomorphic Lung Carcinoma.pdf - 673.00 kB<br>|- Immunotherapy in oncogenic addicted NSCLC.pdf - 3.40 MB<br>|- Immune targets and therapies for SCLC.pdf - 4.20 MB<br>|- I-O until PD.pdf - 1.60 MB<br>|- I-O monotherapy.pdf - 1.70 MB<br>|- How to define it  How to treat it.pdf - 1.50 MB<br>|- How can ESMO help to implement personalised treatment in clinical practice.pdf - 3.20 MB<br>|- How accurate are we in measuring quality of life.pdf - 1.50 MB<br>|- First-line immunotherapy options for patients without an oncogene driver.pdf - 3.40 MB<br>|- Final Analysis of the Phase 3 KEYNOTE-042 Study Pembrolizumab (Pembro) Versus Platinum-Based Chemotherapy (Chemo).pdf - 2.20 MB<br>|- Facts and myths of liquid biopsy.pdf - 3.10 MB<br>|- Experiences from the German Network Genomic Medicine.pdf - 2.40 MB<br>|- Evaluation and challenges of advanced practice lung cancer nurses in current context.pdf - 663.00 kB<br>|- Epidemiology and asbestos ban  European picture.pdf - 2.80 MB<br>|- EPAC-Lung Pooled Analysis of Circulating Tumor Cells in Advanced Non-Small Cell Lung Cancer.pdf - 678.00 kB<br>|- Entrectinib in NTRK Fusion-Positive Non-Small Cell Lung Cancer (NSCLC).pdf - 528.00 kB<br>|- Entrectinib in Locally Advanced or Metastatic ROS1 Fusion-Positive Non-Small Cell Lung Cancer (NSCLC).pdf - 827.00 kB<br>|- elcc 2019 mystic subsequent tx presentation final.pdf - 671.00 kB<br>|- EGFR-TKIs plus bevacizumab demonstrated survival benefit than EGFR-TKIs alone in EGFR-mutant NSCLC patients with multiple brain metastases.pdf - 345.00 kB<br>|- Efficacy and safety of nintedanib + docetaxel in lung adenocarcinoma patients (pts) following treatment with immune checkpoint inhibitors (ICIs).pdf - 299.00 kB<br>|- Efficacy and safety of first-line durvalumab (D) ± tremelimumab (T) vs platinum-based chemotherapy (CT) based on clinical characteristics in patien.pdf - 906.00 kB<br>|- Early stage NSCLC.pdf - 1.80 MB<br>|- Early stage lung cancer The importance of co-morbidity.pdf - 1.60 MB<br>|- Early stage lung cancer  Progress in TNM.pdf - 1.90 MB<br>|- Do we need a molecular board in our hospital.pdf - 4.10 MB</p>
<p><a href="https://bpcam.bemobtrk.com/go/2ceec3aa-1ca2-46d6-b9ff-aaa5c184517c?jno=790" target="_blank" rel="noopener">How to download</a></p>

    </div>

    
    
    

      <footer class="post-footer">

        


        
    <div class="post-nav">
      <div class="post-nav-item">
    <a href="/2020/ERSCH_726/" rel="prev" title="ERSCH">
      <i class="fa fa-chevron-left"></i> ERSCH
    </a></div>
      <div class="post-nav-item">
    <a href="/2020/Drama_171/" rel="next" title="Drama">
      Drama <i class="fa fa-chevron-right"></i>
    </a></div>
    </div>
      </footer>
    
  </article>
  
  
  

  </div>


          </div>
          

<script>
  window.addEventListener('tabs:register', () => {
    let activeClass = CONFIG.comments.activeClass;
    if (CONFIG.comments.storage) {
      activeClass = localStorage.getItem('comments_active') || activeClass;
    }
    if (activeClass) {
      let activeTab = document.querySelector(`a[href="#comment-${activeClass}"]`);
      if (activeTab) {
        activeTab.click();
      }
    }
  });
  if (CONFIG.comments.storage) {
    window.addEventListener('tabs:click', event => {
      if (!event.target.matches('.tabs-comment .tab-content .tab-pane')) return;
      let commentClass = event.target.classList[1];
      localStorage.setItem('comments_active', commentClass);
    });
  }
</script>

        </div>
          
  
  <div class="toggle sidebar-toggle">
    <span class="toggle-line toggle-line-first"></span>
    <span class="toggle-line toggle-line-middle"></span>
    <span class="toggle-line toggle-line-last"></span>
  </div>

  <aside class="sidebar">
    <div class="sidebar-inner">

      <ul class="sidebar-nav motion-element">
        <li class="sidebar-nav-toc">
          Table of Contents
        </li>
        <li class="sidebar-nav-overview">
          Overview
        </li>
      </ul>

      <!--noindex-->
      <div class="post-toc-wrap sidebar-panel">
          <div class="post-toc motion-element"><ol class="nav"><li class="nav-item nav-level-1"><a class="nav-link" href="#ELCC2019"><span class="nav-number">1.</span> <span class="nav-text">ELCC2019</span></a></li></ol></div>
      </div>
      <!--/noindex-->

      <div class="site-overview-wrap sidebar-panel">
        <div class="site-author motion-element" itemprop="author" itemscope itemtype="http://schema.org/Person">
  <p class="site-author-name" itemprop="name">baidupan</p>
  <div class="site-description" itemprop="description">baidupan</div>
</div>
<div class="site-state-wrap motion-element">
  <nav class="site-state">
      <div class="site-state-item site-state-posts">
          <a href="/archives/">
        
          <span class="site-state-item-count">943</span>
          <span class="site-state-item-name">posts</span>
        </a>
      </div>
      <div class="site-state-item site-state-categories">
        <span class="site-state-item-count">1</span>
        <span class="site-state-item-name">categories</span>
      </div>
  </nav>
</div>



      </div>

    </div>
  </aside>
  <div id="sidebar-dimmer"></div>


      </div>
    </main>

    <footer class="footer">
      <div class="footer-inner">
        

<div class="copyright">
  
  &copy; 
  <span itemprop="copyrightYear">2020</span>
  <span class="with-love">
    <i class="fa fa-user"></i>
  </span>
  <span class="author" itemprop="copyrightHolder">baidupan</span>
</div>
  <div class="powered-by">Powered by <a href="https://hexo.io" class="theme-link" rel="noopener" target="_blank">Hexo</a> v3.9.0
  </div>
  <span class="post-meta-divider">|</span>
  <div class="theme-info">Theme – <a href="https://muse.theme-next.org" class="theme-link" rel="noopener" target="_blank">NexT.Muse</a> v7.7.0
  </div>

        








      </div>
    </footer>
  </div>

  
  <script src="/lib/anime.min.js"></script>
  <script src="/lib/velocity/velocity.min.js"></script>
  <script src="/lib/velocity/velocity.ui.min.js"></script>
<script src="/js/utils.js"></script><script src="/js/motion.js"></script>
<script src="/js/schemes/muse.js"></script>
<script src="/js/next-boot.js"></script>



  















  

  

</body>
</html>
